



FOR PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANTS INFORMATION DISCLOSURE
STATEMENT

SUPPLEMENTAL

(Use several sheets if necessary)

ATTY. DOCKET NO.

3818.02-5

SERIAL NO.

10/613,639

APPLICANT: ALAN BRUCE MONTGOMERY

FILING DATE: JULY 3, 2003

GROUP 1616

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
QHAA	P2	6	5	1	8	2	3	9	02/2003	KUO, ET AL.	514	2			
	G1	5	8	7	5	7	7	6	03/1999	VAGHEFI	128	203.15			
	H1	4	8	8	8	9	9	8	12/26/1989	BUZZA, ET AL.	73	864.21			
QHAA	I1	5	9	9	4	3	4	0	11/30/1999	MAITI, ET AL.	514	192			
		DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO	
	M1	WO	01	3	4	2	3	2	5/17/2001	PCT	11	00	X		
QHAA	N1	EP	0	2	9	7	5	80	1/20/1999	EP	417	12	X		

OTHER

ART (Including Author, Title, Date, Pertinent Pages, Etc.)

QHAA	T1		John A. Bosso, et al., Efficacy of Aztreonam in Pulmonary Exacerbations of Cystic Fibrosis, <u>The Pediatr. Infect. Dis. J.</u> , 6:393-397 (1987).
	U1		James L. Cook, M.D., Gram-Negative Bacillary Pneumonia in the Nosocomial Setting, <u>The American Journal of Medicine</u> , 88:3C-34S-37S.
	V1		A. Boccazzi, et al., The Pharmacokinetics of Aztreonam and Penetration into the Bronchial Secretions of Critically Ill Patients, <u>Journal of Antimicrobial Chemotherapy</u> , 23:401-407 (1989).
	W1		Harold C. Neu, M.D., Aztreonam Activity, Pharmacology and Clinical Uses, <u>The American Journal of Medicine</u> , 88:3C-2S-3C-6S.
	X1		John J. LiPuma, MD, <i>Burkholderia cepacia</i> , Management Issues and New Insights, <u>Clinics in Chest Medicine</u> , 19/3:473-486 (September 1998).
	Y1		Stephen C. Aronoff, et al., <i>In Vitro</i> Activities of Aztreonam, Piperacillin, and Ticarcillin Combined with Amikacin Against Amikacin-Resistant <i>Pseudomonas aeruginosa</i> and <i>P. cepacia</i> Isolates from Children with Cystic Fibrosis, <u>Antimicrobial Agents and Chemotherapy</u> , 25/2:279-280 (February 1984)).
	Z1		John A. Bosso, et al., <i>In Vitro</i> Activities of Combinations of Aztreonam, Ciprofloxacin and Ceftazidime Against Clinical Isolates of <i>Pseudomonas aeruginosa</i> and <i>Pseudomonas cepacia</i> from Patients with Cystic Fibrosis, <u>Antimicrobial Agents and Chemotherapy</u> , 34/3:487-488 (March 1990).
QHAA	TT		John M. Mattsen, et al., The Use of Aztreonam in the Cystic Fibrosis Patient, <u>Pediatr. Infect. Dis. J.</u> , 8/9:S117-S119 (1989).
of provided	UU		Lisa Saiman, MD, Antimicrobial Resistance Among <i>Burkholderia</i> , <i>Serratia</i> and <i>Alcaligenes</i> Isolates Studied by the CF Efferal Center for Susceptibility and Synergy Testing, 1998 Cystic Fibrosis Conference, Symposium Session Summaries, 118-119 (1998).
QHAA	VV		Preston W. Campbell III, MD., et al., Use of Aerosolized Antibiotics in Patients with Cystic Fibrosis, Consensus Conference, pp. 775-789 (September 1999).
	WW		Dapena Fernandez J., et al., Inhaled Aztreonam Therapy in Patients with Cystic Fibrosis Colonized with <i>Pseudomonas aeruginosa</i> , <u>Spanish Annals on Pediatrics</u> , 40/3 (1994).
	XX		Gerald C. Smaldone, et al., Aerosolized Antibiotics: Current and Future, <u>Respiratory Care</u> , 45/6:667-675 (June 2000).
	YY		Thomas G. O'Riordan, MD, Inhaled Antimicrobial Therapy: From Cystic Fibrosis to the Flu, <u>Respiratory Care</u> , 45/7:836-845 (July 2000).
	ZZ		Robert G. Bell, et al., Stability of Intravenous Mixtures of Aztreonam and Cefoxitin, Gentamicin, Metronidazole, or Tobramycin, <u>American Journal of Hospital Pharmacy</u> , 43:1444-1453 (June 1986).
	TT1		Michael J. James, et al, Stability of Intravenous Mixtures of Aztreonam and Ampicillin, <u>American Journal of Hospital Pharmacy</u> , 42:1095-1100 (May 1985).
	UUI		Despina Daisy Frangoulis, et al., <i>Burkholderia cepacia</i> in Cystic Fibrosis, <u>Am J of Respir Crit Care Med.</u> , 160:1572-1577 (1999).
QHAA	VVI		Diane H. Johnson, et al., Aztreonam, <u>Medical Clinics of North America</u> , 79/4:733-743 (4 July 1995).

QHAT	WW 1	Woo, M.S., et al., Use of Aerosolized Aztreonam in CF Lung Transplant Patients Colonized With <i>Burkholderia cepacia</i> , 2002 Cystic Fibrosis Conference, p. 322-419
	XX1	Petra Borsje, MD, et al., Aerosol Therapy in Cystic Fibrosis: A Survey of 54 CF Centers, <u>Pediatric Pulmonology</u> , 30:368-376 (2000).
	YY1	Rafael Canton, PD, PhD, et al., Lung Colonization with <i>Enterobacteriaceae</i> Producing Extended-Spectrum β -Lactamases in Cystic Fibrosis Patients, <u>Pediatric Pulmonology</u> , 24:213-217 (1997).
	ZZ1	S. Ballesterio, et al., <i>Stenotrophomonas maltophilia</i> in Cystic Fibrosis Patients, 20 th European Cystic Fibrosis Conference, Brussels, Belgium, pp. 18-21 (June 1995).
QHAT	TT1	Sira Carrasco, et al., The General Approach to Cystic Fibrosis Pulmonary Infection in Spain, <u>Cystic Fibrosis Pulmonary Infections: Lessons From Around The World</u> , Chapter 18, pp. 223-230 (1996).

EXAMINER

DATE CONSIDERED

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PVJS CASE: 3818.01-1 (HV)



FOR PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANTS INFORMATION DISCLOSURE
STATEMENT.

SUPPLEMENTAL

(Use several sheets if necessary)

ATTY. DOCKET NO.

3818.02-5

SERIAL NO.

10/613,639

APPLICANT: ALAN BRUCE MONTGOMERY

FILING DATE: JULY 3, 2003

GROUP 1616

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
JHAA	AAA	4	7	7	5	6	7	0	10/4/88	Sykes, et al.	514	210	1/19/81	
	BBB	4	9	4	6	8	3	8	8/7/90	Floyd, et al.	514	210	7/28/86	
	CCC	20840009126							1/15/04	Pilkiewicz	424	46	3/5/03	
	DDD	4	5	7	2	8	0	1	2/25/86	Matsuo, et al.	260	245.4	5/31/83	
	EEE	4	6	1	0	8	2	4	9/9/86	Trüner	540	355	10/9/84	
JHAA	FFF	4	6	7	3	7	3	9	6/16/87	Matsuo, et al.	540	355	9/18/85	
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
JHAA	MM	0	2	9	7	5	8	0		Europe	417	12	X	

OTHER

ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

1/5/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PVJS CASE: 3818.01-1 (HV)